MINYANVILLE ORIGINAL Peregrine Pharmaceuticals’ (NASDAQ:PPHM) stock is plunging after the company said Monday that investors should not rely on previously reported study results for an experimental lung cancer drug because there were problems with the trial. The company said it discovered “major discrepancies” involving patient test results in a mid-stage study of the experimental drug bavituximab. Peregrine blamed a vendor and said it’s reviewing the problem. “In the meantime investors should not rely on clinical data that the company disclosed on or before September 7” for its lung cancer trial testing bavituximab Peregrine says in a statement. Peregrine is ...